Biogen (BIIB) Misses Q1 EPS by 76c, Announces CEO Transition

Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.62, $0.76 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.5 billion.

• Announces CEO Transition
• Reaffirms FY Guidance

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Virtuix delays Q1 FY2027 earnings report amid accounting firm switch
• EquipmentShare.com Inc. (EQPT) Reports Q2 EPS of $0.18; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c